Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment.

Genomics - 1 Dec 2005

Simon Jason S, Karnoub Maha C, Devlin David J, Arreaza Maria G, Qiu Ping, Monks Stephanie A, Severino Michael E, Deutsch Paul, Palmisano Joanne, Sachs Alan B, Bayne Marvin L, Plump Andrew S, Schadt Eric E

Abstract excerpt

Niemann-Pick C1-like 1 (NPC1L1) is an intestinal cholesterol transporter and the molecular target of ezetimibe, a cholesterol absorption inhibitor demonstrated to reduce LDL-cholesterol (LDL-C) both as monotherapy and when co-administered with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). Interestingly, significant interindividual variability has been observed for rates of intestinal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Azetidines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Black or African American

Share to Cholesterol, LDL

Share to Ezetimibe

Share to Hispanic or Latino

Share to Intestinal Absorption

Share to Phytosterols

Source

Identifiers

PMID: 16297596
DOI: 10.1016/j.ygeno.2005.08.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment.PMID 16297596Read ↗

NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe.Semantic proximity Read ↗

Efficacy of ezetimibe is not related to NPC1L1 gene polymorphisms in a pilot study of Chilean hypercholesterolemic subjects.Semantic proximity Read ↗

Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease.Semantic proximity Read ↗

A SNP of NPC1L1 affects cholesterol absorption in Japanese.Semantic proximity Read ↗

Analysis of Niemann-Pick C1-like 1 (NPC1L1) genetic polymorphisms and haplotypes in Chinese Han population.Semantic proximity Read ↗

In-vitro characterization of the six clustered variants of NPC1L1 observed in cholesterol low absorbers.Semantic proximity Read ↗

Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe.Semantic proximity Read ↗

Gene polymorphism and frequencies of the NPC1L1 gene (rs2072183, rs217434 and rs217428) in Japanese patients with dyslipidemia.Semantic proximity Read ↗

The c.-133A > G polymorphism in NPC1L1 gene influences the efficacy of ezetimibe monotherapy on apolipoprotein A1 in hyperlipidemic patients.Semantic proximity Read ↗

Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer.Semantic proximity Read ↗

Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly.Semantic proximity Read ↗

NPC1L1: evolution from pharmacological target to physiological sterol transporter.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.